Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Novel cadherin conjugates enter the clinic
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
Boehringer slims down in SIRPα
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
PMV hopes for rezatapopt redemption
The disappointing Pynnacle trial is set to yield registrational data.
Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
